Ofloxacin Capsules

The main ingredient of this product is: ofloxacin. Molecular weight: C18H20FN3O4

This product is a capsule, and the contents are off-white or slightly yellow powder.

Oral. Common dosage for adults: 1. Bronchial infection, lung infection: 0.3g once, twice a day, course of treatment 7 to 14 days. 2. Acute simple lower urinary tract infection: 0.2g once, twice a day, course of treatment 5 to 7 days; complicated urinary tract infection: 0.2g once, twice a day, course of treatment 10 to 14 days. 3. Prostatitis: 0.3g once, twice a day, course of treatment 6 weeks; Chlamydia cervicitis or urethritis, 0.3g once, twice a day, course of treatment 7 to 14 days. 4. Simple gonorrhea: 0.4g once, single dose. 5. Typhoid fever: 0.3g once, twice a day, course of treatment 10 to 14 days. 6. For Pseudomonas aeruginosa infection or more severe infection, the dose can be increased to 0.4g once, twice a day.

1. Gastrointestinal reactions: abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioneurotic edema. Photosensitivity reactions are less common. 4. Occasionally, the following may occur: (1) epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. (2) interstitial nephritis manifestations such as hematuria, fever, and rash. (3) phlebitis. (4) crystalluria, which is more common when used in high doses. (5) joint pain. 5. A small number of patients may experience elevated serum aminotransferase, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

Precautions for children: The safety of this product in infants and adolescents under 18 years of age has not been determined. However, this product can cause joint lesions when used in several young animals. Therefore, it should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women, and lactating women should suspend breastfeeding when using this product. Precautions for the elderly: Elderly patients often have impaired renal function, and since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

Urine alkalinization doses can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2β), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Although this product has a small effect on the metabolism of theophylline, theophylline blood drug concentration should still be measured and the dose adjusted when used in combination. This product can increase the blood drug concentration of cyclosporine when used in combination with cyclosporine, and the blood concentration of cyclosporine must be monitored and the dose adjusted. Although this product has a small enhancement on the anticoagulant warfarin when used in combination, the patient's prothrombin time should also be closely monitored when used in combination.

Keep away from light and store in sealed container.

0.1g*20s

24 months